What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Lebrikizumab has shown effectiveness in clinical trials compared to placebo, achieving significant improvements in EASI scores. However, it has not been directly compared with standard treatments like dupilumab or tralokinumab, leading to uncertainty about its relative efficacy. The indirect comparisons suggest comparable effectiveness, but the lack of direct evidence limits the strength of the claim.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for lebrikizumab are within the acceptable range for NICE when compared to other biological treatments. However, it is not cost-effective when compared to JAK inhibitors, indicating a context-dependent value that is defensible under certain conditions.
Is there quality-of-life evidence payers weigh? — Quality of life
The treatment has been associated with improvements in quality of life as measured by the DLQI, although the primary trials did not collect this composite outcome directly. The committee acknowledged that the EASI 75 is a rigorous measure and that improvements in DLQI are expected to correlate with EASI reductions, supporting a moderate benefit in HRQoL.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Lebrikizumab has a favorable safety profile with mostly mild to moderate adverse effects reported in clinical trials. Serious adverse events are rare, and the overall tolerability is considered good compared to existing systemic treatments.
Was the drug compared against what payers expect? — Comparator Selection
While lebrikizumab was compared to placebo in trials, the lack of direct comparisons with standard treatments like dupilumab or tralokinumab raises concerns. The indirect comparisons used in the analysis are not ideal, leading to a suboptimal assessment of its relative effectiveness.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a representative population of patients aged 12 years and older with moderate to severe atopic dermatitis. However, there are some concerns regarding the generalizability of results due to varying eligibility criteria across studies.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Lebrikizumab can be integrated into existing treatment pathways with minor adjustments, as it is positioned as an alternative for patients who have not responded to systemic treatments. The administration process aligns well with current practices.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of lebrikizumab is manageable, especially considering the commercial arrangement that provides a discount. The overall resource use is aligned with the expected outcomes, making it a reasonable option for the Healthcare.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by multiple phase 3 trials, although there are some methodological concerns regarding the indirect comparisons and the absence of direct head-to-head trials. Overall, the evidence is credible but has limitations.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the treatment’s comparative effectiveness and the implications of the indirect comparisons. While the unmet need for effective treatments is acknowledged, the uncertainties surrounding the evidence may restrict its use.
